Gilead And Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program April 2, 2024
Edgewood Oncology raises $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors April 2, 2024
Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML April 2, 2024
Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML April 2, 2024
First Participant dosed in Ph 3 Study (Neoshot) of IBI310 + Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy April 2, 2024
First Patient Dosed in Ph 1/2a Trial of IMM-6-415 in Advanced Solid Tumors with RAF/RAS Mutations April 2, 2024
First Patient Dosed in Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C+ve Solid Tumors April 2, 2024
Enrollment of 190 Patients to Support Primary Endpoint Analysis in SELECT-MDS-1 Ph 3 Trial completed April 2, 2024
Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced April 2, 2024
Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study April 2, 2024
Progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia reported April 2, 2024
METIS Ph 3 Trial Met Primary Endpoint of Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Mets from NSCLC April 2, 2024
KRYSTAL-12 Trial of KRAZATI (adagrasib) Meets Primary Endpoint of PFS for Patients with Pretreated KRAS G12C-Mutated NSCLC April 2, 2024
China’s NMPA Accepts Supplemental BLA for enfortumab vedotin with KEYTRUDA for 1L Bladder Cancer April 2, 2024
FDA Priority Review of NDA for Revumenib for the Treatment of R/R KMT2Ar Acute Leukemia April 2, 2024
Savolitinib Supplemental NDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC April 2, 2024
NMPA approves IND application for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma April 2, 2024
Stenoparib development Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer Accelerated April 2, 2024
European Commission Approves KEYTRUDA + Chemo as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable NSCLC at High Risk of Recurrence in Adults April 2, 2024
Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer April 2, 2024
